V5med Lung AI

by V5med Inc.  · Based in Taiwan →Transforming Lung and Heart Diagnostics with Clinically Proven AI.
Oncology Pulmonology Radiology

Contact for pricing
Regulatory Status Disclosed

Overview

V5med Lung AI is a Computer-Aided Detection (CAD) software designed to assist radiologists in detecting pulmonary nodules with diameters ranging from 4 to 30 mm during chest CT examinations for asymptomatic populations. The software leverages a Deep Convolutional Neural Network (CNN) based algorithm to automatically identify and highlight regions of interest with suspected lung nodules. It operates in a concurrent read mode, displaying AI analysis results alongside original CT images to provide adjunctive information and reduce the risk of overlooked findings. The system is compatible with the DICOM 3.0 standard, ensuring broad integration with various imaging equipment and PACS systems. Key functionalities include providing detailed nodule characteristics such as diameter, volume, nodule type, and Lung-RADS score. It can also compare chest CT scans taken at different time points to analyze nodule growth over time by calculating the volume doubling time (VDT), and generate comprehensive reports based on ACR Lung-RADS and Fleischner Society guidelines. Clinical studies have shown that V5med Lung AI can increase nodule detection sensitivity by over 95% and improve radiologist accuracy by up to 20%, while also reducing reading time by approximately 13%.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered lung nodule detection (4-30 mm)
  • Deep Convolutional Neural Network (CNN) algorithm
  • Concurrent read mode for radiologists
  • Detection of ground-glass nodules (GGNs)
  • PACS-integrated and vendor-neutral
  • DICOM 3.0 standard compatible
  • Provides nodule characteristics (diameter, volume, type, Lung-RADS score)
  • Compares CT scans over time for nodule growth analysis (Volume Doubling Time)
  • Generates comprehensive reports based on ACR Lung-RADS and Fleischner Society guidelines
  • Reduces radiologist reading time by 13%

Use Cases

  • Lung cancer screening programs
  • Early detection of lung nodules
  • Assisting radiologists in CT interpretation
  • Monitoring nodule growth over time
  • Routine chest CT workflows

What Physicians Need to Know

Key Capabilities
V5med Lung AI is a Computer-Aided Detection (CAD) software designed to assist radiologists in detecting pulmonary nodules (4-30 mm diameter) in chest CT images of asymptomatic populations. It utilizes a Deep Convolutional Neural Network (CNN) algorithm to automatically detect nodules and provides adjunctive information to highlight regions of interest. The system offers detailed nodule characteristics, including diameter, volume, type, and Lung-RADS score, and can compare scans over time to analyze nodule growth and calculate volume doubling time (VDT). It also supports the detection of ground-glass nodules (GGNs) and can generate comprehensive reports based on ACR Lung-RADS and Fleischner Society guidelines.
Clinical Utility
The tool is clinically validated to improve radiologist performance in nodule detection, showing a significant increase in AUC (from 0.734 to 0.830) and a 13% reduction in reading time (from 133.0 to 115.9 seconds per case). It has demonstrated a 10% reduction in missed cancers (76.7% detection with AI vs. 69.6% unaided) with comparable specificity. V5med Lung AI also significantly improves inter-reader agreement in Lung-RADS scores, enhancing consistency in diagnosis. It is designed to assist in interpreting low-dose CT (LDCT) scans, helping radiologists and pulmonologists efficiently detect early-stage lung nodules and identify suspicious lesions, thereby reducing the risk of misdiagnosis and oversight.
Integration Options
V5med Lung AI is PACS-integrated and vendor-neutral, accepting chest CT images from PACS, RIS, or directly from CT scanners, provided they conform to the DICOM 3.0 standard. The system integrates its algorithm logic and database on a single server for ease of maintenance. Output annotations regarding lung nodules are displayed alongside the original CT images in a concurrent read mode, typically within the hospital's existing DICOM Viewer system.
Compliance Status
V5med Lung AI received U.S. FDA 510(k) clearance (K242919) on March 27, 2025, making it the first Taiwanese company to obtain such approval for low-dose CT-based lung cancer screening AI. It is classified as a Class II medical device and a software-only device (SaMD). The product also holds medical device certifications in Taiwan (TFDA Class II), Vietnam, Indonesia, Thailand, and Malaysia.
Pricing Model
One reported business model in Thailand is a 'Monthly rental to hospitals across the country,' aiming to provide accessible conditions and prices.
User Experience
The software is designed to be an adjunctive tool, not a replacement for radiologist judgment, displaying AI analysis results alongside original CT images within familiar DICOM Viewer systems. It uses circular icons for confirmed nodules and rectangular labels for nodule information, including CADe determination score and diameter. Comprehensive user training and documentation are provided by certified professionals during installation.
Support Quality
V5med offers ongoing support, including email notifications for version updates and issue resolutions. Scheduled on-site software updates are performed by their staff to ensure optimal performance and security. A support team is available for expert assistance with complex issues.
Implementation Complexity
The V5med Lung AI is an offline-capable application, generally distributed via a USB 3.0 flash drive. Installation is performed on-site by factory engineers or professionally trained and certified dealers/Field Application Engineers (FAEs), following a meticulous process that includes pre-installation assessment and configuration. The system requires installation on a server host and connection to the hospital's PACS system via intranet.
Evidence Base
The system's efficacy is supported by a pivotal multi-reader multi-case (MRMC) clinical study involving 16 radiologists and 340 chest CT scans, demonstrating superior radiologist performance and reduced reading times. Clinical validation data met FDA standards for detection rate, case-level sensitivity, and false-positive control. A large-scale clinical trial titled 'Artificial Intelligence Assisted Computational Tomographic Detection of Lung Nodules for Prognostic Cancer Examination' was published in Biomedicines in 2023.
Physician Tip

V5med Lung AI serves as a valuable adjunctive tool for radiologists, enhancing the detection of pulmonary nodules and improving diagnostic efficiency. Its ability to detect small nodules (4-30mm), including ground-glass nodules, and provide detailed characteristics like Lung-RADS scores, can significantly aid in early lung cancer screening and management. Physicians should integrate this tool in a concurrent read mode, leveraging its AI-generated annotations to complement their clinical judgment, rather than replacing it. The longitudinal comparison feature for nodule growth analysis is particularly useful for follow-up protocols. Ensure proper training for optimal utilization and be aware of the system's limitations, such as potential false negatives/positives under certain image quality conditions.

V5med Lung AI is designed for seamless integration into existing radiology workflows. It is highly compatible, accepting DICOM 3.0 standard images from various CT scanners, PACS, and RIS systems. The system operates on a dedicated server and displays its AI analysis results directly within the hospital's familiar DICOM Viewer interface, minimizing disruption to current reading practices. On-site installation and configuration by certified professionals ensure proper setup and connectivity within the hospital's intranet. Its vendor-neutral approach makes it adaptable to diverse clinical environments.

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentOffline operation, generally distributed via USB 3.0 flash drive with on-site installation by certified engineers. Installed on a server host and connected to PACS via intranet.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status 1 AI-estimated

V5med Lung AI received U.S. FDA 510(k) clearance (K242919) on March 27, 2025. It is a Computer-Aided Detection (CAD) software indicated for assisting radiologists in detecting pulmonary nodules (4-30 mm) during chest CT examinations for asymptomatic populations.

Integrations
EHR Not specified
Specialties Oncology, Pulmonology, Radiology

What the Web Says

V5med Lung AI is a software-only, AI-powered computer-aided detection (CAD) tool designed to assist radiologists in identifying pulmonary nodules (4-30mm) in chest CT images of asymptomatic individuals. It utilizes a Deep Convolutional Neural Network (CNN) based algorithm and integrates with existing PACS/RIS systems or directly with CT scanners. Clinical studies have shown that V5med Lung AI improves radiologist performance in nodule detection, reduces reading time, and enhances inter-reader agreement. The system received U.S. FDA 510(k) clearance in March 2025.

Overall: Positive

Strengths

  • Improved nodule detection sensitivity, with a 10% reduction in missed cancers compared to unaided reads.
  • Reduced radiologist interpretation time by an average of 13%.
  • Enhanced inter-reader agreement among radiologists of different experience levels.
  • Broad compatibility with various imaging equipment due to DICOM 3.0 standard adherence.
  • Designed for seamless integration into diverse clinical environments and existing PACS/RIS systems.
  • FDA-approved, indicating adherence to rigorous regulatory standards.

Limitations

  • Not intended to replace a radiologist's critical judgment or diagnostic processes and should not be used in isolation.
  • Not applicable for patients with obvious abnormalities like large thoracic tumors (>30mm), diffuse lung metastasis, malignant pleural effusion, or those with a history of lung tumors, lung surgery, or interstitial lung disease.
  • Potential for software malfunction or data compromise if the computer is infected with malware.
  • Installation requires on-site delivery and setup by factory engineers or certified dealers.
  • Racial diversity in pivotal study skewed (92.8% White), reflecting the NLST source population.
  • Standalone performance metrics (sensitivity, specificity) are not fully disclosed in public summaries, only relative to predicate devices.

Based on reviews from: V5med Lung AI (v5med.com), V5med Lung AI | FDA Radiology AI Device - X-ray Interpreter, K242919 - Ining Cheng - accessdata.fda.gov, V5med's AI Lung Nodule Detection System Receives U.S. FDA Approval | Healthcare+ B2B, Clinical Evaluation of the V5-LU01 AI Software in Thoracic CT for V5med Inc. - CenterWatch, V5 Technologies nets TFDA approval of Lung Image Aided Interpretation Software, V5med Lung AI - OncologyAI Registry, Transforming Lung and Heart Diagnostics with Clinically Proven AI. - V5med Inc. Introduction, V5med Inc. Introduction, Artificial Intelligence Assisted Computational Tomographic Detection of Lung Nodules for Prognostic Cancer Examination: A Large-Scale Clinical Trial - PMC, (PDF) Artificial Intelligence Assisted Computational Tomographic Detection of Lung Nodules for Prognostic Cancer Examination: A Large-Scale Clinical Trial - ResearchGate

Last updated: 2026-07-20

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate V5med Lung AI

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

V5med Inc.
V5med Becomes First Taiwanese Company to Receive U.S. FDA 510(k) Clearance for Lung Cancer Screening AI
V5med's Lung AI system received U.S. FDA 510(k) clearance in March 2025, making it the first Taiwanese company to achieve this for low-dose CT-based lung cancer screening. The AI solution has been adopted by over 40 hospitals in Taiwan and is expanding into global markets.
2025-06
X-ray Interpreter
V5med Lung AI | FDA Radiology AI Device - X-ray Interpreter
V5med Lung AI, an AI-powered software, received FDA approval on March 27, 2025, to assist radiologists in detecting pulmonary nodules from 4 to 30 mm in chest CT images. Clinical studies demonstrated improved radiologist performance and reduced reading time by 13%.
2025-03
Healthcare+ B2B
V5med's AI Lung Nodule Detection System Receives U.S. FDA Approval | Healthcare+ B2B
Taiwanese smart healthcare startup V5med announced its AI-assisted lung nodule detection system received U.S. FDA 510(k) clearance on March 27, 2025. This approval is a significant step for V5med's expansion into American and Middle Eastern markets.
2025-04
Grand View Research
Lung Cancer Screening Software Market Size, Share & 2031 Growth Trends Report
V5med's Lung AI received FDA clearance in March 2025, contributing to the growing lung cancer screening software market. The report highlights how AI can cut radiologist interpretation time and reduce false positives, with cloud-based solutions leading market share.
2026-01
V5med Inc.
V5med and Clairvo Technologies to Enter into an Business Alliance Agreement on Medical Device Programs Assisting in the Detection of Nodules from Chest CT Images
V5med Inc. and Clairvo Technologies Co., Ltd. entered into an exclusive business alliance agreement in April 2024 to obtain regulatory approvals and market V5med's chest CT imaging diagnostic support software in Japan. The product assists in detecting lung nodules and generating reports.
2024-04
Manila Bulletin
Special press event previews September's showcase of Taiwan's soft & hard power
V5med Inc. showcased its AI-assisted software, V5med Lung AI, at a special press event previewing the Taiwan Expo in the Philippines in August 2025, setting new standards in precision medicine.
2025-08
CenterWatch
Clinical Evaluation of the V5-LU01 AI Software in Thoracic CT for V5med Inc.
A retrospective, multi-reader, multi-case clinical study is being conducted to prove that radiologist performance aided by V5med Lung AI is superior for detecting lung nodules and does not significantly increase reading time. The study involves 16 radiologists and approximately 350 retrospective CT studies.
2024-07
FDA
K242919 - 510(k) Premarket Notification - FDA
This FDA 510(k) premarket notification details the V5med Lung AI (K242919), a Computer-Aided Detection (CAD) software designed to assist radiologists in detecting pulmonary nodules during chest CT examinations. The document outlines its intended use, device description, and performance data.
2025-03

Videos

Product demos, reviews, and walkthroughs for V5med Lung AI.

View all on YouTube

Frequently Asked Questions

V5med Lung AI is a Computer-Aided Detection (CAD) software designed to assist radiologists in detecting pulmonary nodules (4-30 mm) during chest CT examinations, operating in a concurrent read mode. It integrates with PACS/RIS or directly with CT scanners, analyzes DICOM 3.0 images, and provides output annotations including nodule characteristics like diameter, volume, type, and Lung-RADS score. The system can also compare scans over time to analyze nodule growth and generate comprehensive reports based on guidelines.
V5med Lung AI has received U.S. FDA 510(k) clearance as of March 27, 2025, and also holds TFDA and Thai medical device approvals. The software is installed on-site by professionally trained and certified dealers or Field Application Engineers (FAEs) to ensure strict adherence to regulatory standards. While specific data privacy protocols like HIPAA/GDPR are not detailed in the provided information, the on-site installation and offline operation suggest a controlled environment for data handling.
V5med Lung AI is an adjunctive tool and does not replace the radiologist's critical judgment or diagnostic processes; it should not be used in isolation from the original CT series. While AI models generally show high sensitivity, some studies indicate they may have lower specificity than radiologists, potentially leading to false positives. The performance of AI tools can also degrade over time, necessitating post-deployment monitoring.
V5med Lung AI is one of several AI-assisted lung nodule detection systems available, with others including solutions from companies like Lunit, Optellum, Rayscape, and contextflow. While V5med Lung AI has demonstrated superior sensitivity in some clinical studies, the overall performance of AI tools can vary, with some studies showing AI outperforming radiologists in sensitivity but sometimes having lower specificity. The choice of an AI solution often depends on specific clinical needs, integration capabilities, and local validation.
While specific pricing for V5med Lung AI is not detailed, AI radiology solutions typically offer subscription-based, pay-per-use, or custom/tiered pricing models. AI solutions may qualify for additional reimbursement if they can generate new diagnostic information, such as malignancy scores of pulmonary nodules, rather than merely duplicating physician work. Studies have shown that AI-supported risk stratification can be cost-effective, with potential for improved life expectancy at a reasonable incremental cost.
Clinical studies have shown that radiologist performance aided by V5med Lung AI is superior for detecting qualified lung nodules compared to unaided reads, with sensitivity being superior with AI assistance. The system has also been shown to decrease radiologist interpretation time, with one study reporting a reduction from 133.0 seconds unaided to 115.9 seconds per case when assisted by V5med Lung AI. This suggests improved efficiency and potentially reduced missed cancers.
V5med Lung AI is an application capable of offline operation, typically distributed via a USB 3.0 flash drive. Factory engineers or professionally trained and certified dealers/Field Application Engineers (FAEs) personally deliver and meticulously install the software on-site, ensuring adherence to regulatory standards. The system is designed to analyze medical images conforming to the DICOM 3.0 standard, ensuring broad compatibility with various CT scanners and seamless integration into diverse clinical environments.

Related Tools

FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.
AI-based support system for skin cancer diagnostics
German Cancer Research Center (DKFZ)
Clinical Decision Support & Reference
Scientists at the German Cancer Research Center have developed an AI-based support system for skin cancer diagnostics that explains its decisions, increasing doctors' confidence in both the AI and their own diagnoses.
eyonis® LCS
Median Technologies
Oncology AI
eyonis® LCS is an FDA 510(k) cleared AI/machine learning-powered software for the detection and diagnosis of lung cancer, helping clinicians detect and characterize suspicious parenchymal pulmonary nodules earlier on low-dose CT scans.
Lumea Digital Pathology
Lumea
Clinical Decision Support & Reference
Lumea is a specialty-specific digital pathology platform that covers the entire diagnostic workflow, from biopsy to final report, and integrates AI tools from partners like Paige and Mindpeak.
Azra AI
Azra AI
Clinical Decision Support & Reference
Azra AI is an AI platform that swiftly analyzes, identifies, and classifies cancer patients, triaging those needing therapy and follow-up to enhance oncology care. It is deployed at more than 1,500 sites and integrated with leading EHRs.
Trial Library
Trial Library
Drug Discovery & Research
Trial Library's AI-native platform is embedded in community oncology practices to identify eligible patients for oncology clinical trials. It integrates clinical trials into routine care, activating providers, identifying eligible patients, and navigating them through the trial lifecycle across health systems, biopharma, and payers.

See all Oncology AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.